-transparent.png){kind=logo}
Postmortem studies have associated Alzheimer's disease (AD) with regionally increased oxidative damage to brain. Lacking, however, is a specific marker of oxidative damage to brain that may be measured during life. We tested the hypothesis that cerebrospinal fluid (CSF) concentrations of F2-isoprostanes (F2-IsoPs), stable products of arachidonate peroxidation, are increased in CSF of AD patients. CSF from lateral ventricles (VF) was analyzed from 11 AD patients and 11 control subjects who participated in a rapid autopsy program. VF F2-IsoP concentrations were significantly elevated in AD patients compared with control subjects (72 +/- 7 vs 46 +/- 4 pg/ml) and were significantly linearly correlated with brain weight (-0.3 pg/ml/g, r2 = 0.32). These results suggest that quantification of CSF F2-IsoP concentrations may provide a useful biomarker of central nervous system oxidative damage in AD.
T J Montine, and
W R Markesbery, and
J D Morrow, and
L J Roberts
October 1995,
Neuroscience letters,
T J Montine, and
W R Markesbery, and
J D Morrow, and
L J Roberts
November 1999,
Brain research,
T J Montine, and
W R Markesbery, and
J D Morrow, and
L J Roberts
March 2011,
Neuromolecular medicine,
T J Montine, and
W R Markesbery, and
J D Morrow, and
L J Roberts
January 2014,
Journal of Alzheimer's disease : JAD,
T J Montine, and
W R Markesbery, and
J D Morrow, and
L J Roberts
May 2015,
Alzheimer's & dementia : the journal of the Alzheimer's Association,
T J Montine, and
W R Markesbery, and
J D Morrow, and
L J Roberts
March 2009,
Neurobiology of disease,
T J Montine, and
W R Markesbery, and
J D Morrow, and
L J Roberts
March 2007,
Neuroscience letters,
T J Montine, and
W R Markesbery, and
J D Morrow, and
L J Roberts
March 1999,
Neurology,
T J Montine, and
W R Markesbery, and
J D Morrow, and
L J Roberts
December 1994,
Journal of neuroendocrinology,
T J Montine, and
W R Markesbery, and
J D Morrow, and
L J Roberts
July 2001,
Neuroscience letters,
